Vascular diseases (Paris, France)最新文献

{"title":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.","authors":"Abdul Mueez Alam Kayani, Muhammad Faiq Umar, Daniel Navarro-Martinez, Alan Garcia, Muhammad Affan Rashid, Ricky E Lemus-Zamora","doi":"10.1016/j.vasdi.2026.02.004","DOIUrl":"10.1016/j.vasdi.2026.02.004","url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, particularly among high-risk patients. Despite the availability of multiple lipid lowering therapies, many patients fail to achieve the guideline recommended low-density lipoprotein cholesterol (LDL-C) targets. Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor optimizes lipid profile by blocking the exchange of cholesterol esters from high-density lipoprotein cholesterol (HDL-C) to Apolipoprotein B (ApoB) containing lipoproteins. This study evaluates the efficacy and safety of obicetrapib as an adjunctive therapy in high-risk ASCVD patients.</p><p><strong>Methods: </strong>Online databases were searched. Outcomes included percentage changes in LDL-C, HDL-C, non-HDL-C, total cholesterol, triglyceride, ApoB, lipoprotein (a) [Lp(a)] and risk of any adverse events (AE), AE leading to discontinuation, acute kidney injury (AKI), transaminase or creatine kinase (CK) elevation and hypertension. Risk ratio (RR) for categorical outcomes and mean difference (MD) for continuous outcomes were reported using 95% confidence intervals (CI).</p><p><strong>Results: </strong>Three studies with 3088 patients (mean age 64 ± 11, 37% female) were selected. Obicetrapib significantly reduced LDL-C (-31.75%), non-HDL-C (-29.35%), triglyceride (-5.61%), Lp(a) (-35.67%), ApoB (-19.37%), and increased HDL-C (+125.94%) with no difference in total cholesterol levels. Obicetrapib was not associated with increased risk for any AE, AE leading to discontinuation, AKI, transaminase or CK elevation, and hypertension.</p><p><strong>Conclusion: </strong>Obicetrapib substantially improved lipid profiles in high-risk ASCVD patients on maximally tolerated lipid lowering therapy, without increased short-term adverse events. However, further long-term randomized studies are needed to confirm sustained efficacy, long-term safety, and potential impacts on clinical cardiovascular outcomes.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"144-154"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Epitact® Light Legs phlebological insoles on symptoms and quality of life in patients with chronic venous disease.","authors":"Samuel Béliard, Tom Lecocq, Axelle Thibert, Laurent Mourot, Nicolas Tordi","doi":"10.1016/j.vasdi.2025.12.001","DOIUrl":"10.1016/j.vasdi.2025.12.001","url":null,"abstract":"<p><strong>Background: </strong>The management of chronic venous disease is based on the targeted treatment of the arch of the foot and the gait. Epitact® Light Legs phlebological insoles is a medical device designed to stimulate and optimize venous return in patients with chronic venous disease.</p><p><strong>Method: </strong>Semell'Innov is a prospective, randomized controlled, two-arm single center study. The goal was to measure the impact of insoles on symptoms (VEINES-QOL/Sym) and quality of life (CIVIQ14) in patients with stage C2S chronic venous disease (CEAP classification - Clinical C, Etiological E, Anatomical A, and Pathophysiological P). Forty-six subjects were evaluated for two months, during which they randomly used either their usual non-phlebological insoles or phlebological insoles.</p><p><strong>Result: </strong>Our data showed that wearing phlebological insoles led to a reduction in symptoms (VEINES-QOL/Sym score - inclusion visit: 35.6±6.9; usual non-phlebological insoles: 38.7±6.5; phlebological insoles: 45.1±5.5; P<0.001) and improved quality of life (CIVIQ14 score - inclusion visit: 19.8±16.3; usual non-phlebological insoles: 13.9±12.6; phlebological insoles: 8.0±11.1; P<0.001).</p><p><strong>Conclusion: </strong>These results suggest that the use of the Epitact® Light Legs phlebological insoles may have a beneficial effect on the symptoms and quality of life of patients with chronic venous disease.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How French vascular physicians treat cancer associated superficial vein thrombosis?","authors":"Simon Soudet, Lina Khider, Tristan Mirault, Florian Scotté, Laurent Bertoletti, Marie-Antoinette Sevestre","doi":"10.1016/j.vasdi.2026.01.134","DOIUrl":"10.1016/j.vasdi.2026.01.134","url":null,"abstract":"<p><strong>Background: </strong>Superficial vein thrombosis (SVT) is a common and well-known condition. Active cancer increases the risk of thrombosis, particularly for SVT associated with catheters in the upper limbs. Despite its frequency, cancer-associated SVT management is not addressed by current evidence-based guidelines, leading to heterogeneous clinical practices.</p><p><strong>Objective: </strong>To describe the current management strategies for cancer-associated SVT among French vascular physicians.</p><p><strong>Methods: </strong>We conducted a national cross-sectional declarative survey distributed to all the members of both the French Society of Vascular Medicine and the French Association for Oncological Supportive Care. The questionnaire explored demographics and clinical approaches to SVT associated with cancer, both in the lower and upper limbs, through proposed scenarios.</p><p><strong>Results: </strong>A total of 136 physicians responded, of whom 132 (97.1%) were vascular specialists. SVT of the lower limbs was considered cancer-associated in 15% of cases in daily practice. Among respondents, 102 (75.7%) declared modifying their treatment strategy in the presence of cancer. Fondaparinux 2.5mg/day (44.1%) and curative-dose low molecular weight heparin (30.9%) were the most common initial treatments. Treatment lasted six weeks in 50.7% of cases and was extended as long as cancer remained active in 38.7%. Oral relay was considered in 19.1% of cases, mainly with apixaban. For upper limb SVT, 27.7% were considered cancer-related, and one third were catheter-associated. Treatment was commonly stopped upon catheter removal.</p><p><strong>Conclusion: </strong>This survey reveals substantial variability in the treatment of cancer-associated SVT. The absence of dedicated trials and specific recommendations highlights the urgent need for prospective studies to guide management in this complex clinical setting.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"77-81"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146196240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep venous free-floating thrombus: A review and meta-analysis.","authors":"Mario Maufus, Lucia Mazzolai, Beatrice Terriat, Gilles Pernod","doi":"10.1016/j.vasdi.2025.11.002","DOIUrl":"10.1016/j.vasdi.2025.11.002","url":null,"abstract":"<p><strong>Background: </strong>The main risk associated with deep vein thrombosis (DVT) is pulmonary embolism (PE). The risk of PE can be stratified, particularly based on the location of the DVT, i.e. proximal or distal. Another potentially embolic feature that has been reported is the presence of a free-floating thrombus (FFT). However, this phenomenon remains controversial and raises several unanswered questions.</p><p><strong>Aims: </strong>We aimed to determine whether the presence of FFT has any clinical significance regarding the risk of pulmonary embolism.</p><p><strong>Materials and methods: </strong>We conducted a systematic literature review and a meta-analysis using the keywords \"free-floating thrombus\" and \"pulmonary embolism\" in the MEDLINE database.</p><p><strong>Results: </strong>A total of 35 publications were found to be relevant. The presence of FFT was associated with a higher risk of primary PE (77 vs. 23% in the absence of FFT; OR 3.3, 95% CI 1.4-7.7; P<0.02) and secondary PE (11 vs. 1.6% in the absence of FFT; OR 2.2, 95% CI 1.3-3.9; P<0.004). The incidence of secondary symptomatic PE was not statistically significant.</p><p><strong>Conclusion: </strong>The free-floating characteristic of DVT is associated with a higher risk of initial PE at diagnosis and a higher risk of secondary PE, although it does not appear to be associated with an increased risk of secondary symptomatic PE. However, our meta-analysis lacks sufficient power to confirm this conclusion.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare and emerging arterial diseases of the supra-aortic trunks: Diagnostic and therapeutic insights.","authors":"Dominique Stephan, Amer Hamadé, Corina Mirea, Mihaela Cordeanu","doi":"10.1016/j.vasdi.2025.12.002","DOIUrl":"10.1016/j.vasdi.2025.12.002","url":null,"abstract":"<p><p>Diseases of the supra-aortic trunks (SATs) encompass a broad and heterogeneous group of arterial disorders, ranging from classic inflammatory vasculitis to recently recognized, non-atherosclerotic entities. While atherosclerosis remains the predominant cause of SATs stenosis, up to 10% of carotid or subclavian artery lesions occur in patients without established cardiovascular risk factors. These rare conditions are increasingly identified through advances in vascular imaging, which now allow detailed analysis of the vessel wall. Among the most notable emerging entities are Transient Perivascular Inflammation of the Carotid artery (TIPIC) syndrome, carotid web, and Eagle syndrome. Their recognition has reshaped our understanding of carotid and subclavian artery pathology, revealing a spectrum that extends beyond inflammatory and atheromatous mechanisms to include structural, mechanical, and developmental abnormalities. This comprehensive overview explores rare and emerging arterial diseases involving the SATs, highlighting recent diagnostic and therapeutic insights. We emphasize the pivotal role of multimodal imaging in differentiating these entities and propose an integrated diagnostic approach combining clinical, imaging, and pathophysiological perspectives.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"89-96"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous leukocytoclastic vasculitis leading to extensive digital necrosis as the only COVID-19 clinical manifestation.","authors":"Romane Pouy, Messaline Bermejo, Anne Durlach, Firouzé Bani-Sadr","doi":"10.1016/j.vasdi.2025.12.003","DOIUrl":"10.1016/j.vasdi.2025.12.003","url":null,"abstract":"<p><p>Digital necrosis is now a well-established complication of COVID-19 infection, but data are sparse regarding the pathophysiology. We present the case of digital necrosis secondary to cutaneous leukocytoclastic vasculitis in a patient with COVID-19 infection. After histologic confirmation of vasculitis, the patient was given methylprednisolone leading to an improvement that enabled limited amputation.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"97-99"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146042393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe elastic fiber fragmentation/loss is correlated with Marfan syndrome in patients with an ascending aortic aneurysm.","authors":"Nour Bakour, Yihua Liu, Adriano Burcheri-Curatolo, Mohamed-Yassine Benzha, Jean-Pierre Villemot, Juan-Pablo Maureira, Guillaume Gauchotte","doi":"10.1016/j.vasdi.2026.01.136","DOIUrl":"10.1016/j.vasdi.2026.01.136","url":null,"abstract":"<p><strong>Context and objectives: </strong>Aortic wall degeneration was described by a consensus statement published in 2016 by the Society for Cardiovascular Pathology (SCP) and Association for European Cardiovascular Pathology (AECP). The aim of this study was to determine if histopathologic features could predict the presence of genetic syndrome, to assess the prognostic value of histological findings, and to correlate it with clinical data.</p><p><strong>Methods: </strong>This study included 85 patients operated in the CHRU of Nancy. When available (n=80), all histological sections were reviewed and scored following the SCP/AECP recommendations.</p><p><strong>Results: </strong>Translamellar mucoid extracellular matrix accumulation (MEMA-T) was significantly associated with MFS, only in patients<60years old (P=0.015) but did not allow to accurately predict the existence of MFS. Severe Elastic fiber fragmentation/loss (EFFL) was significantly associated with MFS (P=0.018). Using ROC analyses, we found that the optimal age threshold to predict MFS was 60years old, leading to 100% sensitivity but 51% specificity. The sensitivity and specificity of severe EFFL in order to predict MFS were 88% and 62%, respectively (88% and 65% under the age of 60years old; 100% and 57% under the age of 50years old).</p><p><strong>Conclusion: </strong>In conclusion, we found a significantly more frequent severe elastic fibers fragmentation and/or loss in patients with a MFS. These patients are younger and we recommend to systematically search for a Marfan syndrome for patients under 60years old with an ascending aortic aneurysm whatever the histological data. Further studies are required to evaluate the added value of histological criteria, particularly EFFL, for the diagnosis of Marfan syndrome.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"82-88"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147314607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute upper limb ischemia due to cervical rib-related thoracic outlet syndrome.","authors":"Oumayma Lahjouji, Youssef Mhamdi Alaoui, Ismail Chaouche, Hajar Ouazzani, Chahdi Amal Akammar, Badr Alami, Moulay Youssef Alaoui Lamrani, Meryem Boubbou, Mustapha Maâroufi, Nizar El Bouardi","doi":"10.1016/j.vasdi.2026.01.135","DOIUrl":"10.1016/j.vasdi.2026.01.135","url":null,"abstract":"<p><p>Thoracic outlet syndrome (TOS) results from the compression of neurovascular structures at the thoracic outlet. The clinical presentation of arterial compression ranges from chronic ischemic symptoms, such as upper limb pallor, coldness, and exercise-induced claudication, to acute vascular complications including arterial thrombosis, which may progress to limb-threatening ischemia. We report the case of a 33-year-old patient with no significant medical history who presented with acute ischemia of the left upper limb. Radiological investigations revealed TOS with a cervical rib as the underlying cause of acute limb ischemia. This case underscores the pivotal role of imaging in establishing the etiological diagnosis and identifying vascular complications, thereby enabling rapid therapeutic management.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"100-103"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular management of a hypoglossal canal dural arteriovenous fistula.","authors":"Liliana Igreja, João Pedro Filipe, Viriato Alves, João Xavier, José Pedro R Pereira","doi":"10.1016/j.vasdi.2026.01.139","DOIUrl":"10.1016/j.vasdi.2026.01.139","url":null,"abstract":"<p><strong>Background: </strong>Dural arteriovenous fistulas (DAVFs) involving the hypoglossal canal are rare vascular anomalies, typically manifesting with pulsatile tinnitus or lower cranial nerve dysfunction. Treatment planning must account for their highly variable and often evolving venous drainage patterns.</p><p><strong>Case report: </strong>We present the case of a 54-year-old male with right-sided pulsatile tinnitus and episodic headaches. Imaging revealed a DAVF centered at the right hypoglossal canal with multiple arterial feeders and dominant intracranial retrograde drainage into the inferior petrosal and cavernous sinuses. Initial transvenous embolization of the isolated inferior petrosal sinus achieved partial occlusion, with temporarily symptomatic relief. Recurrence of the bruit correlated with a major shift in venous drainage toward the cervical epidural plexus. A second embolization via the anterior epidural venous route allowed direct access to the fistulous pouch, resulting in definitive occlusion. The patient remained asymptomatic thereafter.</p><p><strong>Discussion: </strong>This case highlights the dynamic angioarchitecture of hypoglossal canal DAVFs and the challenges posed by its multiple arterial feeders and venous outlets, which can obscure the precise location of the fistulous point. In our patient, these complexities necessitated a staged and sequential endovascular approach to achieve complete fistula occlusion and resolution of symptoms.</p><p><strong>Conclusion: </strong>DAVFs of the hypoglossal canal demand high-resolution imaging and adaptive treatment strategies considering its dynamic nature. Transvenous embolization via the cervical epidural venous system offers a safe and effective route for definitive fistula occlusion without neurological dysfunction.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"104-108"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146222765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke-related mortality in Mahajanga, Madagascar in 2019: A study based on death notifications.","authors":"Odilon Rahamefy Randrianasolo, Lala Andriamasinavalona Rajaonarison, Nomena Finiavana Rasaholiarison, Jenny Larissa Rakotomanana, Julien Razafimahefa, Noel Zodaly, Alain Djacoba Tehindrazanarivelo","doi":"10.1016/j.vasdi.2025.11.001","DOIUrl":"10.1016/j.vasdi.2025.11.001","url":null,"abstract":"<p><strong>Background: </strong>Stroke mortality is a growing concern in low-income countries, including Madagascar. This study examines stroke-related deaths in Mahajanga, a coastal city in western Madagascar, using death registers to better understand the local epidemiological burden of stroke.</p><p><strong>Methods: </strong>A retrospective analysis of death registers from the Municipal Hygiene Office (BMH) in Mahajanga was conducted for 2019. All deaths recorded within the city were included, excluding non-residents and incomplete records. Stroke-related deaths were identified using ICD-9/10 codes or explicit descriptions. Demographic data and years of life lost (YLL) were analyzed.</p><p><strong>Results: </strong>Among 1701 reported deaths, 161 (9.4%) were attributed to stroke. Stroke accounted for 9.4% of all-cause mortality and 14.5% of deaths among individuals aged≥50 years. The mean age of stroke-related deaths was 61.3 years, and males predominated (sex ratio 1.3). More than half (52.1%) of stroke deaths occurred at home. Stroke accounted for 2324.7 years of life lost (YLL) and represented 59.62% of all neurological-related deaths.</p><p><strong>Conclusion: </strong>Stroke was identified as a major cause of mortality in Mahajanga. The findings indicate a rising trend in stroke-related deaths over recent decades, reflecting persistent challenges in stroke prevention and management. High rates of garbage coding (26.27%) in death certification limit data reliability.</p>","PeriodicalId":520901,"journal":{"name":"Vascular diseases (Paris, France)","volume":" ","pages":"67-69"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}